Related Experiment Video
Updated: May 27, 2026
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease
Aristóteles Álvarez-Cardona1, Ana Luisa Rodríguez-Lozano, Lizbeth Blancas-Galicia
1Clinical Immunology Department, Instituto Nacional de Pediatría, Insurgentes sur 3700-C, Insurgentes Cuicuilco Coyoacan CP, Mexico City, Mexico.
Objectives:
Chronic granulomatous disease is a rare phagocyte disorder characterized by an increased susceptibility to infections and inflammatory complications. We describe two patients with chronic granulomatous disease (CGD) complicated by macrophage activation syndrome (MAS) (secondary hemophagocytic lymphohistiocytosis) treated with intravenous immunoglobulin (IVIG).
Methods:
A report of two cases of CGD complicated by MAS who were successfully treated with IVIG was made, and a comparison was made with ten other cases reported in the literature.
Results:
MAS is a severe potentially fatal complication of CGD. Most cases are associated with Burkholderia cepacia and leishmaniasis infection. The treatment of these patients varies between centers, and one example is the use of the HLH-2004 protocol. IVIG could be an effective first line option for this complication in CGD patients.
Conclusions:
The exaggerated inflammatory response characteristic of CGD patients could play a role in the development of this complication. IVIG appears to be a safe and effective first line treatment in these patients.
